Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial

Eunice S. Wang, Jessica K. Altman, Mark D. Minden, Ruishan Wu, Elizabeth Shima Rich, Jason E. Hill

Blood (2021) 138 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2021-145362

Published: 2021

Journal Articles

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3 mut+ acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Eunice S. Wang, Michael Heuser, Pau Montesinos, Elizabeth Shima Rich, Ruishan Wu, Bhavik J. Pandya, Manasee V. Shah

Blood (2021) 138 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2021-144977

Published: 2021

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation

Henry C. Fung, FRCP, MD, Muhammed Alikhan, Lela Buckingham, PhD, John J. Maciejewski, MD, PhD, Reem Karmali, MD, Kent W Christopherson, II, PhD, Elizabeth Shima Rich, MD, PhD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Sunita Nathan, MD

Blood (2012) 120 (21): 4162.

https://doi.org/10.1182/blood.V120.21.4162.4162

Published: 2012

Journal Articles

Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,

Jennifer Tornatta, MS, ANP, John J. Maciejewski, MD, PhD, Sunita Nathan, MD, Bruce Mcleod, MD, Sridevi Palaparthy, MBA, MS, Elizabeth Shima Rich, MD, PhD, Kent W Christopherson, II, PhD, Stephanie A. Gregory, MD, Henry C. Fung, FRCP, MD

Blood (2011) 118 (21): 4061.

https://doi.org/10.1182/blood.V118.21.4061.4061

Published: 2011

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Koen M. Van Besien, MD, Wendy Stock, MD, Elizabeth Shima Rich, MD, PhD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Peter O'Donnell, MD, Justin Kline, MD, Vu H. Nguyen, MD, Paula Del Cerro, RN, Richard A. Larson, MD, Andrew Artz, MD MS

Blood (2011) 118 (21): 1948.

https://doi.org/10.1182/blood.V118.21.1948.1948

Published: 2011

Journal Articles

A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma — Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,

Henry C. Fung, FRCP, MD, Sunita Nathan, MD, Neel B. Shah, MD, John J. Maciejewski, MD, PhD, Elizabeth Shima Rich, MD, PhD, Jennifer Tornatta, MS, ANP, Nancy Licciardi, Parameswaran Venugopal, MD, Reem Karmali, MD, Stephanie A. Gregory, MD

Blood (2011) 118 (21): 4205.

https://doi.org/10.1182/blood.V118.21.4205.4205

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Hongtao Liu, MD, PhD, Elizabeth Shima Rich, MD, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, M.D., Susana Marino, M.D., Justin Kline, MD, Vu H. Nguyen, MD, John M Cunningham, MD, Richard A. Larson, MD, Paula Del Cerro, RN, Linda Schroeder, RN, Lisa Pape, RN, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD MS, Koen M. Van Besien, MD

Blood (2011) 118 (21): 830.

https://doi.org/10.1182/blood.V118.21.830.830

Published: 2011

Journal Articles

CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.

Eun-Sun Yoo, MD, PhD, Sucheta Jagan, MS, Sridevi Palaparthy, MBA, MS, Mary A Enriquez, RN, ANP, Karen Samuels, RN, MS, NP-C, Sarah Walters, RN, MSN, GNP-BC, APN, Elizabeth Mieras, MMS, PA-C, Laura A Paganessi, MA, Chu-Myong Seong, MD, Elizabeth Shima Rich, MD, PhD, Henry C. Fung, FRCP, MD, Kent W. Christopherson, II, PhD

Blood (2010) 116 (21): 3714.

https://doi.org/10.1182/blood.V116.21.3714.3714

Published: 2010

Journal Articles

Cytokine Treatment of CD34 + Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex Vivo Culture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.

Laura A Paganessi, MA, Lydia Luy Tan, BS, Sucheta Jagan, MS, Robin Frank, BS, Antonio M. Jimenez, MD, Elizabeth Shima Rich, MD, PhD, Sunita Nathan, MD, John Maciejewski, MD, PhD, Henry C. Fung, FRCP, MD, Kent W. Christopherson, II, PhD

Blood (2010) 116 (21): 1460.

https://doi.org/10.1182/blood.V116.21.1460.1460

Published: 2010

Journal Articles

Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.

Antonio M. Jimenez, MD, George Behrens, MD, John Maciejewski, MD, PhD, Norman Wool, MD, Elizabeth Shima Rich, MD, PhD, Reem Karmali, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Henry C. Fung, FRCP, MD, Sunita Nathan, MD

Blood (2010) 116 (21): 1283.

https://doi.org/10.1182/blood.V116.21.1283.1283

Published: 2010

Journal Articles

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Blood (2009) 114 (22): 2081.

https://doi.org/10.1182/blood.V114.22.2081.2081

Published: 2009

Journal Articles

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Sarah Larson, MD, Nicholas Campbell, MD, Dezheng Huo, PhD, Andrew Artz, MD, MS, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, MD, Lucy A Godley, MD, PhD, Elizabeth Shima Rich, MD, PhD, Michael Thirman, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2009) 114 (22): 1048.

https://doi.org/10.1182/blood.V114.22.1048.1048

Published: 2009

Journal Articles

Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT).

Lucy A Godley, Uchenna O. Njiaju, Margaret Green, Howard Weiner, Shang Lin, PhD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Koen van Besien, MD, Christopher Daugherty, MD, Yanming Zhang, Michelle M. Le Beau, PhD, Wendy Stock, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 1030.

https://doi.org/10.1182/blood.V114.22.1030.1030

Published: 2009

Journal Articles

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Koen van Besien, MD, Justin Kline, Lucy A Godley, MD, PhD, Richard A. Larson, MD, Vu H. Nguyen, MD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Wendy Stock, MD, Amittha Wickrema, PhD, Scott Allen, BA, Paula del Cerro, Sarah Horowitz, Lisa Pape, RN, Linda Schroeder, RN, Andrew Artz, MD, MS

Blood (2009) 114 (22): 197.

https://doi.org/10.1182/blood.V114.22.197.197

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, Ph.D., Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, MD, Justin Kline, MD, Vu H. Nguyen, MD, Guadalupe Martinez, BS, Paula del Cerro, RN, Lisa Pape, RN, Linda Schroeder, RN, Scott Allen, BA, Sarah Horowitz, BA, John Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Amittha Wickrema, PhD, Koen van Besien, MD

Blood (2009) 114 (22): 3378.

https://doi.org/10.1182/blood.V114.22.3378.3378

Published: 2009

Journal Articles

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Vaishalee P. Kenkre, MD, Sarah Horowitz, Richard A. Larson, MD, Andrew Artz, MD, MS, Elizabeth Shima Rich, MD, PhD, Yanming Zhang, M.D., M.S., Michelle M. Le Beau, PhD, Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Michael Thirman, MD, Koen van Besien, MD, Wendy Stock, MD

Blood (2009) 114 (22): 3395.

https://doi.org/10.1182/blood.V114.22.3395.3395

Published: 2009

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study

Koen Van Besien, Frederick Locke, MD, Justin Kline, Lucy Godley, MD, PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD, MS

Blood (2008) 112 (11): 4381.

https://doi.org/10.1182/blood.V112.11.4381.4381

Published: 2008

NARROW

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3 mut+ acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation

Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma — Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.

Cytokine Treatment of CD34 + Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex Vivo Culture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.

Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT).

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only